The IL1R1 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human KYSE-30 esophageal squamous cell carcinoma line, carrying a targeted disruption of the IL1R1 gene. This polyclonal loss-of-function model enables stable and complete abrogation of IL1R1-dependent signaling across a genetically diverse cell pool, avoiding the limitations of transient knockdown or pharmacological inhibition.
The parental KYSE-30 cell line is a well-differentiated invasive human esophageal squamous cell carcinoma model with epithelial morphology, commonly employed to study esophageal cancer pathogenesis, metastasis, and therapeutic response. The knockout cells retain the fundamental characteristics of the parental line while allowing specific interrogation of IL1R1-mediated pathways.
IL1R1 encodes the receptor for interleukin-1 alpha and beta (IL1A, IL1B). Upon ligand binding, IL1R1 recruits the co-receptor IL1RAP and the adaptor MYD88, triggering activation of IRAK4 and IRAK1 kinases, which in turn signal to TRAF6. This leads to activation of NF-??B transcription factors (NFKB1, RELA) and MAP kinases including JNK (MAPK8), which phosphorylate AP-1 components JUN and FOS. Downstream target genes include IL6 and IL8. The natural antagonist IL1RN negatively regulates this cascade. Thus, IL1R1 governs a central inflammatory signaling network influencing cell survival, proliferation, and immune responses.
In esophageal squamous cell carcinoma, IL-1 signaling promotes tumor progression by enhancing proliferation, migration, invasion, and immune evasion through constitutive NF-??B and MAPK activity. Ablation of IL1R1 in KYSE-30 cells abolishes these cytokine-driven responses, providing a defined model to dissect cell-autonomous effects of IL-1 in esophageal cancer and to evaluate the pathway as a therapeutic target.
Researchers can use this model for biochemical validation of signal transduction (e.g., western blot for phospho-p65, phospho-JNK), RT-qPCR analysis of inflammatory gene expression, NF-??B reporter assays, and functional assays such as migration, invasion, and proliferation. It also supports drug target validation and studies of immune evasion mechanisms. For more information or to discuss specific protocols, please contact Ascent Research.
